Sign In  |  Register  |  About Santa Clara  |  Contact Us

Santa Clara, CA
September 01, 2020 1:39pm
7-Day Forecast | Traffic

  • Search Hotels in Santa Clara

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

77.09 -0.56 (-0.72%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,439,023
Open 78.00
Bid (Size) 77.09 (5)
Ask (Size) 77.20 (1)
Prev. Close 77.65
Today's Range 77.01 - 78.62
52wk Range 57.16 - 89.74
Shares Outstanding 1,253,809,440
Dividend Yield 3.68%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Stocks Going Ex-Dividend In June 2023
The following is a short list of some of the many stocks going ex-dividend during the next month, which can be helpful for traders and investors interested in the stock trading technique known as... 
Via Talk Markets
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga

Performance

YTD
-9.72%
-9.72%
1 Month
-7.73%
-7.73%
3 Month
-4.70%
-4.70%
6 Month
-9.53%
-9.53%
1 Year
+18.97%
+18.97%

More News

Read More
Promising Developments Announced Ahead of 2023 ASCO Annual Meeting’s Oral Presentations
Via FinancialNewsMedia
Exposures Product Safety
Arcus Biosciences Soars On Roche's 'Meaningful' Results In A New Cancer Drug Class
Via Investor's Business Daily
Mount Gilead, NC Author Publishes Children's Book
Via PR Leap
A Look Into Gilead Sciences' Debt
Via Benzinga
Looking Into Gilead Sciences's Recent Short Interest
Via Benzinga
Gilead Sciences Stock: Bear vs. Bull
Via The Motley Fool
CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Severe Renal Impairment, Including Those on Dialysis
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences to Present at Upcoming Investor Conference
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences Stock Reaches 80-Plus Relative Strength Rating Benchmark
Via Investor's Business Daily
3 Relatively Safe Stocks to Buy if a Recession Is on the Way
Via The Motley Fool
Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings
Via MarketBeat
Exposures Product Safety
3 Analyst Upgrades That Smart Investors Won’t Ignore
Via InvestorPlace
Gilead and Kite Oncology to Showcase Advances Across the Pipeline Aiming to Address Unmet Needs in Cancer Care at ASCO 2023
From Gilead Sciences, Inc.
Via Business Wire
Gilead Appoints Cindy Perettie Executive Vice President of Kite
From Gilead Sciences, Inc.
Via Business Wire
GDC Stock Alert: Why Is GD Culture Group Up 106% Today?
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For May 16, 2023
Via Benzinga
Why Is Guardforce AI (GFAI) Stock Up Today?
Via InvestorPlace
GILD Stock Price Predictions: Is Gilead Sciences Really Worth $100?
Via InvestorPlace
Gilead Sciences To Rally Around 28%? Here Are 10 Other Analyst Forecasts For Tuesday
Via Benzinga
Gilead Sciences and Arcus Biosciences Expand Partnership to Include Research Programs in Inflammation
From Arcus Biosciences
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Gilead Strengthens Early Pipeline in Oncology and Inflammation Through the Acquisition of XinThera
From Gilead Sciences, Inc.
Via Business Wire
American Express, Gilead Sciences And This US Oil Giant On CNBC's 'Final Trades'
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SantaClara.com & California Media Partners, LLC. All rights reserved.